In a randomised controlled trial, Craft et al. examined the influence of administering insulin (20 or 40 IU) through the ViaNase nasal delivery device on cognitive function and glucose homeostasis in individuals with AD or MCI over 4 months [111]. The gene discussed is INS; the disease is Alzheimer disease.